When Amgen Inc. (NASDAQ: AMGN) reported its third-quarter financial results after the markets closed on Thursday, the company said that it had $3.02 in earnings per share (EPS) and $5.81 billion in revenue. Consensus estimates from Thomson Reuters had called for $2.79 in EPS and revenue of $5.74 billion. In the same period of last year, the biotech giant posted EPS of $2.72 and $5.72 billion in revenue.
In terms of guidance for the full year, the company expects to have EPS in the range of $11.40 to $11.55 and revenues between$22.6 billion and $22.8 billion. Both forecasts increased from their previous levels. The consensus estimates for the full year are $11.36 in EPS and $22.77 billion in revenue.
The company generated $2.5 billion of free cash flow in the third quarter, compared with $2.8 billion in the third quarter of 2015. The board of directors declared a dividend of $1.00 per share on October 14 that will be paid on December 8 to all stockholders of record as of November 16.
Top 5 Biotech Stocks To Own Right Now: Amgen Inc.(AMGN)
- [By ]
Booker’s report took on other companies as well. Pfizer (PFE) , Gilead Sciences (GILD) , AbbVie (ABBV) , Amgen (AMGN) , Bristol-Myers Squibb (BMY) Eli Lilly & Co. (LLY) , and Mylan NV (MYL) are cited for everything from raising drug prices, to stock buybacks and putting shareholder interest before that of the public.
- [By Joseph Griffin]
South Dakota Investment Council lowered its stake in Amgen (NASDAQ:AMGN) by 59.4% during the 1st quarter, HoldingsChannel reports. The fund owned 77,041 shares of the medical research company’s stock after selling 112,589 shares during the quarter. South Dakota Investment Council’s holdings in Amgen were worth $13,134,000 at the end of the most recent quarter.
- [By Keith Speights]
That difficulty hasn’t stopped market research firm EvaluatePharma from trying, though. EvaluatePharma recently published a list of the drugmakers with the projected highest value creation from pipelineproducts between 2018 and 2024. Here’s why Novartis (NYSE:NVS), AbbVie (NYSE:ABBV), Celgene (NASDAQ:CELG), AstraZeneca (NYSE:AZN), and Amgen (NASDAQ:AMGN) ranked at the top.
- [By Keith Speights]
The big reason Humira will maintain its position at the top is the U.S. market. U.S. sales of the drug are projected to be around $12.2 billion in 2024. That’s not much lower than Humira’s 2017 U.S. sales of nearly $12.4 billion. Will Amgen’s (NASDAQ:AMGN) biosimilar Amjevita, which will go on sale in the U.S. effective Jan. 31, 2023, really make that small of a dent in Humira’s sales? Not really. The impact will be greater than the 2024 projections indicate.
Top 5 Biotech Stocks To Own Right Now: ArQule Inc.(ARQL)
- [By Stephan Byrd]
ArQule, Inc. (NASDAQ:ARQL) Director Ronald M. Lindsay acquired 23,900 shares of the company’s stock in a transaction on Thursday, May 10th. The stock was acquired at an average price of $2.67 per share, for a total transaction of $63,813.00. Following the purchase, the director now directly owns 43,900 shares of the company’s stock, valued at $117,213. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
- [By Money Morning Staff Reports]
But Blink and our other penny stocks to watch are unlikely to continue to lock in such spectacular gains in June. After looking at our 10 top penny stocks to watch this month, we’ll show you a small-cap stock with great profit potential in its future…
Penny Stock Current Share Price Law Month’s Gain
Blink Charging Co. (Nasdaq: BLNK) $7.07 439.85%
Senes Tech Inc. (Nasdaq: SNES) $1.27 175.40%
Vivis Inc. (Nasdaq: VVUS) $0.77 150.41%
Adomani Inc. (Nasdaq: ADOM) $1.49 137.68%
NF Energy Saving Co. (Nasdaq: NFEC) $2.34 134.88%
Vaalco Energy Inc. (NYSE: EGY) $2.15 109.06%
Heat Biologics Inc. (Nasdaq: HTBX) $2.35 99.12%
ArQule Inc. (Nasdaq: ARQL) $4.88 90.74%
LiqTech International Inc. (NYSE: LIQT) $0.66 85.60%
Transenterix Inc. (NYSE: TRXC) $3.46 77.84%
While last month’s gains are tremendous, they also illustrate the inherent dangers that come with investing in penny stocks.
- [By Ethan Ryder]
Get a free copy of the Zacks research report on ArQule (ARQL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Lisa Levin] Gainers
Melinta Therapeutics, Inc. (NASDAQ: MLNT) shares surged 20.6 percent to $6.39. WBB Securities upgraded Melinta Therapeutics from Hold to Speculative Buy.
Shoe Carnival, Inc. (NASDAQ: SCVL) shares climbed 17.2 percent to $30.87 after the company reported upbeat quarterly earnings.
Acorn International, Inc. (NYSE: ATV) shares rose 15.2 percent to $28.804 after the company declared a special one-time cash dividend of $14.97 per ADS.
Foot Locker, Inc. (NYSE: FL) gained 15 percent to $53.35 after the company reported better-than-expected results for its first quarter.
Sears Hometown and Outlet Stores, Inc. (NASDAQ: SHOS) surged 14.2 percent to $2.625.
ArQule, Inc. (NASDAQ: ARQL) rose 13 percent to $5.12 after gaining 4.86 percent on Thursday.
Quality Systems, Inc. (NASDAQ: QSII) gained 12.8 percent to $16.97 after the company posted better-than-expected FQ4 results.
Loma Negra Compañía Industrial Argentina Sociedad Anónima (NYSE: LOMA) shares rose 12 percent to $12.94.
ArQule, Inc. (NASDAQ: ARQL) shares rose 12 percent to $5.07.
Mirati Therapeutics, Inc. (NASDAQ: MRTX) climbed 11.4 percent to $43.50.
Zai Lab Limited (NASDAQ: ZLAB) gained 11.3 percent to $24.7000.
Zymeworks Inc. (NASDAQ: ZYME) rose 9.7 percent to $19.64.
Park City Group, Inc. (NASDAQ: PCYG) climbed 9 percent to $7.90.
Roku, Inc. (NASDAQ: ROKU) gained 7.9 percent to $38.82 after Citron reversed previously bearish position on the stock.
Sears Holdings Corporation (NASDAQ: SHLD) shares jumped 7.3 percent to $3.55.
Deckers Outdoor Corp (NYSE: DECK) rose 3.5 percent to $107.27 after reporting better-than-expected results for its fiscal fourth quarter.
Check out these big penny stock gainers and losers
- [By Joseph Griffin]
Shares of ArQule, Inc. (NASDAQ:ARQL) were down 5.4% during trading on Wednesday . The company traded as low as $4.71 and last traded at $4.73. Approximately 3,358,864 shares traded hands during trading, an increase of 289% from the average daily volume of 863,008 shares. The stock had previously closed at $5.00.
- [By Lisa Levin] Gainers
Foot Locker, Inc. (NYSE: FL) rose 15.3 percent to $53.50 in pre-market trading after the company reported better-than-expected results for its first quarter.
Evofem Biosciences, Inc. (NASDAQ: EVFM) rose 10.4 percent to $4.58 in pre-market trading. Evofem Biosciences reported closing of public offering of common stock and warrants.
Resonant Inc. (NASDAQ: RESN) rose 7.3 percent to $4.88 in pre-market trading after declining 1.94 percent on Thursday.
SolarEdge Technologies, Inc. (NASDAQ: SEDG) shares rose 5.7 percent to $59.65 in pre-market trading after falling 8.43 percent on Thursday.
Yirendai Ltd. (NYSE: YRD) rose 5 percent to $30.00 in pre-market trading after reporting Q1 results.
Deckers Outdoor Corp (NYSE: DECK) rose 4.9 percent to $108.75 in pre-market trading after reporteingd better-than-expected results for its fiscal fourth quarter.
Blue Apron Holdings, Inc. (NYSE: APRN) rose 4.2 percent to $3.21 in pre-market trading after gaining 3.70 percent on Thursday.
Recro Pharma, Inc. (NASDAQ: REPH) rose 4 percent to $5.85 in pre-market trading after dropping 54.67 percent on Thursday.
ArQule, Inc. (NASDAQ: ARQL) rose 3.8 percent to $4.70 in pre-market trading after gaining 4.86 percent on Thursday.
Babcock & Wilcox Enterprises, Inc. (NYSE: BW) shares rose 2.9 percent to $2.85 in pre-market trading after climbing 7.78 percent on Thursday.
Bilibili Inc. (NASDAQ: BILI) shares rose 2.5 percent to $14.20 in pre-market trading after surging 11.33 percent on Thursday.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
Top 5 Biotech Stocks To Own Right Now: Biogen Idec Inc(BIIB)
- [By Garrett Baldwin]
Markets are keeping a close eye on the 10-year bond, which is hovering near 3% – an important psychological level that is likely to influence future price movements. On Monday, Fox Business Network’s “Varney & Co.” asked Money Morning Chief Investment Strategist Keith Fitz-Gerald if investors should be worried. Here’s what Keith had to say about the 10-year Treasury yield… and how it will affect your stocks and bonds in the future.
The price of Brent crude oil topped $75.00 and hit its highest level since November 2014. Oil traders were eyeing the ongoing efforts of OPEC and Russia to reduce excessive production around the globe, rising demand ahead of peak driving season, and the possibility that the Trump administration will slap Iran with a new round of sanctions.
Three Stocks to Watch Today: KO, GOOGL, SLM
Shares of The Coca-Cola Co.(NYSE: KO) added 1.2% after the firm easily beat earnings and revenue expectations. The firm cited strong demand for its new flavors of Diet Coke and its Coke Zero Sugar. Demand was so strong for the quarter that the firm reported organic sales growth of 5%. The company reported earnings per share of $0.47, topping estimates by a penny. Revenue of $7.6 billion easily beat Wall Street estimates.
Shares of Alphabet Inc. (Nasdaq: GOOGL) seesawed in pre-market hours. The online search giant topped Wall Street earnings and revenue expectations after the bell Monday. However, shares were off 0.5% after executives announced that its business costs were on the rise. The firm’s real estate and computer purchases tripled in one year, to $7.3 billion. About one-third of that total came from its $2.4 billion purchase of the Chelsea Market building in New York City.
Good news for SLM Corp.(NYSE: SLM) investors, but bad news for indebted college students and graduates. The firm – also known as Sallie Mae – topped Wall Street earnings expectations on Monday. The firm said that it increased its loan o
- [By Jim Crumly]
As for individual stocks, Biogen (NASDAQ:BIIB) made headlines with positive results from a trial of an Alzheimer’s drug, and PriceSmart (NASDAQ:PSMT) fell after reporting earnings.
- [By Keith Speights]
Investors haven’t been happy with either Biogen (NASDAQ:BIIB) or Celgene (NASDAQ:CELG) lately. But the level of discontent is much higher with Celgene. The biotech stock has dropped more than 20% so far in 2018, compared to a single-digit percentage decline for Biogen.
- [By Cory Renauer]
Biogen Inc.’s (NASDAQ:BIIB) Alzheimer’s disease hopeful topped the list last year, but repeated failures with experimental drugs that attack the disease from a similar angle have all flopped. Despite the risk, EvaluatePharma estimates aducanumab’s present value ataround$8.4 billion and this figure will rise or fall dramatically when the company reads off results of ongoing pivotal trials, probably in early 2020.
- [By Chris Lange]
The S&P 500 stock posting the largest daily percentage loss ahead of the close Monday was Biogen Inc. (NASDAQ: BIIB) which traded down nearly 4% at $329.58. The stocks 52-week range is $244.28 to $348.84. Volume was 1.2 million matching the daily average of 1.2 million shares.
Top 5 Biotech Stocks To Own Right Now: Alnylam Pharmaceuticals Inc.(ALNY)
- [By Sean Williams, Chuck Saletta, and Brian Feroldi]
So, which biotech stocks should you consider buying in June? That’s a question we posed to three of our healthcare-focused investors. Interestingly enough, mid-cap biotech stocks are the clear flavor of the month. If biotech is on your radar in June, our investors suggest you consider Ionis Pharmaceuticals (NASDAQ:IONS), Spark Therapeutics (NASDAQ:ONCE), and Alnylam Pharmaceuticals (NASDAQ:ALNY).
- [By Logan Wallace]
Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by analysts at Zacks Investment Research from a hold rating to a sell rating. According to Zacks, “Although Alnylam has a broad and promising pipeline, we note that most candidates are in mid stages of development. These candidates still have a long way to go before hitting the market. The company relies highly on collaborators for funding. Any development/regulatory setback would be a negative for the company. However, Alnylam reported positive data from the ATLAS study in the first quarter which led to regulatory filings for its late-stage pipeline candidate patisiran and the FDA set an action date of Aug 11, 2018. The company along with its partners Sanofi and The Medicines Company, restarted fitusiran's ATLAS phase III study and advanced inclisiran in the ORION-9, -10, and -11 phase III studies, respectively, with results expected for both programs in 2019. Alnylam expects to achieve the profile of three marketed products by the end of 2020.”
- [By Brian Orelli]
Alnylam Pharmaceuticals (NASDAQ:ALNY) released first-quarter results last week, but all eyes were looking forward as the company waits for a potential approval of its hereditary TTR amyloidosis (ATTR) drug, patisiran.